SBI-3150

(Anti-pDC/activated B cell antibody)

Indication

SBI-3150 is an antibody drug candidate that can target both pDCs and B cells activated in various autoimmune diseases. Although an antibody drug targeting B cells is already marketed and shows efficacy,SBI-3150 has potential to show less side effects and higher efficacy as a therapeutic drug for autoimmune diseases since it can specifically target activated B cells which play important role in these therapeutic pathway.

Mode of action

SBI-3150 is an antibody against a target specifically expressed on both pDCs and activated B cells.The antibody binds to pDCs producing large amount of IFNα and activated B cells producing autoantibody.It can be applied to autoimmune diseases by killing pDC and activated B cells simultaneously.

Partnering Opportunities

If you are interested in collaborating with SBI Biotech,please contact our business development team.

Direct to Research & Development Dept.
web_sbibt@sbigroup.co.jp
Phone: +81-3-6229-0831

 Back to top